来曲唑联合治疗对卵巢储备正常女性卵巢刺激中卵母细胞获数、胚胎发育和活产率的影响:RIOT试验次要结局
该研究为随机双盲安慰剂对照试验的次要结局分析,纳入159例卵巢储备正常女性,比较促排卵中每日5mg来曲唑与安慰剂的效应。结果显示两组在卵泡募集、获卵数、胚胎质量和活产率方面均无显著差异。
要点
- 来曲唑组与安慰剂组可用胚胎比例相似,为0.31 vs 0.36(平均差-0.05,95%CI -0.12至0.03,P=0.65)。
- 两组每移植临床妊娠率分别为31% vs 39%(风险差8%,95%CI -25%至11%,P=0.65)。
- 两组每移植活产率分别为28% vs 37%(平均差-9%,95%CI -26%至9%,P=0.60),无显著差异。
核心结论
- 来曲唑联合治疗对卵泡募集、获卵数、胚胎质量或活产率均未发现影响。
研究设计与样本
- 随机双盲安慰剂对照试验的次要结局分析,在丹麦四家大学医院生育诊所于2016年8月至2018年11月进行,妊娠结局随访至2023年5月。
- 共纳入159例预期卵巢储备正常(抗苗勒管激素8-32 nmol/l)女性,随机接受每日5mg来曲唑(n=80)或安慰剂(n=79)联合FSH促排卵。
- 共获取1268个卵母细胞,形成386个胚胎,其中129个胚胎在新鲜周期移植,158个胚胎在后续冻融胚胎移植周期移植。
主要发现
- 可用胚胎占获卵比例来曲唑组与安慰剂组分别为0.31 vs 0.36(平均差-0.05,95%CI -0.12至0.03,P=0.65)。
- 每例患者获卵数来曲唑组与安慰剂组分别为8.0 vs 7.9(平均差0.1,95%CI -1.4至1.6,P=0.39)。
- 扳机日13至16mm卵泡获卵机会安慰剂组比来曲唑组高66%(95%CI 24%至108%,P=0.002);≥17mm卵泡获卵机会来曲唑组比安慰剂组高50%(95%CI 2%至98%,P=0.04)。
- ICSI组MII率来曲唑组 vs 安慰剂组为0.75 vs 0.88(平均差-0.14,95%CI -0.22至-0.06,P=0.03)。
- 每移植活产率来曲唑组 vs 安慰剂组为28% vs 37%(平均差-9%,95%CI -26%至9%,P=0.60);每随机女性活产率为24% vs 30%(平均差-6%,95%CI -22%至8%,P=0.60)。
关键数值与推荐
- 临床妊娠率每移植来曲唑组 vs 安慰剂组为31% vs 39%(风险差8%,95%CI -25%至11%,P=0.65),调整后OR为0.8(95%CI 0.4至1.6,P=0.72)。
- 第5天囊胚数每例来曲唑组 vs 安慰剂组为1.5 vs 2.0(P=0.52);第5天玻璃化囊胚数每例为0.8 vs 1.2(平均差-0.4,95%CI -1.0至0.2,P=0.52)。
- 形态学评估显示来曲唑组 vs 安慰剂组发育为更优级别胚胎的OR为0.8(95%CI 0.5至1.3,P=0.68)。
- 培养至第3天高KIDscore™的OR来曲唑组 vs 安慰剂组为1.2(95%CI 0.8至1.9,P=0.68)。
- 累积临床妊娠率来曲唑组 vs 安慰剂组为38% vs 34%(平均差95%CI 8%至16%,P=0.70)。
临床怎么用
- 作者认为,相似的胚胎利用率和质量支持在特定指征(如生育力保存、既往癌症患者或低反应者)的IVF中使用来曲唑联合治疗。
- 作者建议,来曲唑对不同卵泡大小来源的成熟卵母细胞及活产率的影响应通过Meta分析或更大规模的随机对照试验进行评估。
局限性
- 方案允许卵裂期和囊胚期移植及玻璃化,因此必须对其质量进行分类并合并结果。
- 该研究的检验效能针对激素变化,而非胚胎或妊娠结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does letrozole (LZ) co-treatment during ovarian stimulation with gonadotropins for in IVF impact follicle recruitment, oocyte number and quality, embryo quality, or live birth rate (LBR)? SUMMARY ANSWER: No impact of LZ was found in follicle recruitment, number of oocytes, quality of embryos, or LBR. WHAT IS KNOWN ALREADY: Multi-follicle stimulation for IVF produces supra-physiological oestradiol levels. LZ is an aromatase inhibitor that lowers serum oestradiol thus reducing negative feedback and increasing the endogenous gonadotropins in both the follicular and the luteal phases, effectively normalizing the endocrine milieu during IVF treatment. STUDY DESIGN, SIZE, DURATION: Secondary outcomes from a randomized, double-blind placebo-controlled trial (RCT) investigating once-daily 5 mg LZ or placebo during stimulation for IVF with FSH. The RCT was conducted at four fertility clinics at University Hospitals in Denmark from August 2016 to November 2018 and pregnancy outcomes of frozen-thawed embryo transfers (FET) registered until May 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: One hundred fifty-nine women with expected normal ovarian reserve (anti-Müllerian hormone 8-32 nmol/l) were randomized to either co-treatment with LZ (n = 80) or placebo (n = 79). In total 1268 oocytes were aspirated developing into 386 embryos, and morphology and morphokinetics were assessed. One hundred twenty-nine embryos were transferred in the fresh cycle and 158 embryos in a subsequent FET cycle. The effect of LZ on cumulative clinical pregnancy rate (CPR), LBR, endometrial thickness in the fresh cycle, and total FSH consumption was reported. MAIN RESULTS AND THE ROLE OF CHANCE: The proportion of usable embryos of retrieved oocytes was similar in the LZ group and the placebo group with 0.31 vs 0.36 (mean difference (MD) -0.05, 95% CI (-0.12; 0.03), P = 0.65). The size and number of aspirated follicles at oocyte retrieval were similar with 11.8 vs 10.3 follicles per patient (MD 1.5, 95% CI (-0.5; 3.1), P = 0.50), as well as the number of retrieved oocytes with 8.0 vs 7.9 oocytes (MD 0.1, 95% CI (-1.4; 1.6), P = 0.39) in the LZ and placebo groups, respectively. The chance of retrieving an oocyte from the 13 to 16 mm follicles at trigger day was 66% higher (95% CI (24%; 108%), P = 0.002) in the placebo group than in the LZ group, whilst the chance of retrieving an oocyte from the ≥17 mm follicles at trigger day was 50% higher (95% CI (2%; 98%), P = 0.04) in the LZ group than in the placebo group. The proportion of fertilized oocytes with two-pronuclei per retrieved oocytes or per metaphase II oocytes (MII) (the 2PN rates) were similar regardless of fertilization with IVF or ICSI with 0.48 vs 0.57 (MD -0.09, 95% CI (-0.24; 0.04), P = 0.51), and 0.62 vs 0.64 (MD -0.02, 95% CI (-0.13; 0.07), P = 0.78) in the LZ and placebo groups, respectively. However, the MII rate in the ICSI group was significantly lower with 0.75 vs 0.88 in the LZ vs the placebo group (MD -0.14, 95% CI (-0.22; -0.06), P = 0.03). Blastocysts on Day 5 per patient were similar with 1.5 vs 2.0, P = 0.52, as well as vitrified blastocysts per patient Day 5 with 0.8 vs 1.2 in (MD -0.4, 95% CI (-1.0; 0.2), P = 0.52) and vitrified blastocysts per patient Day 6 with 0.6 vs 0.6 (MD 0, 95% CI (-0.3; 0.3), P = 1.00) in the LZ vs placebo group, respectively. Morphologic evaluation of all usable embryos showed a similar distribution in 'Good', 'Fair', and 'Poor', in the LZ vs placebo group, with an odds ratio (OR) of 0.8 95% CI (0.5; 1.3), P = 0.68 of developing a better class embryo. Two hundred and ninety-five of the 386 embryos were cultured in an embryoscope. Morphokinetic annotations showed that the odds of having a high KIDscore™ D3 Day 3 were 1.2 times higher (CI (0.8; 1.9), P = 0.68) in the LZ group vs the placebo group. The CPR per transfer was comparable with 31% vs 39% (risk-difference of 8%, 95% CI (-25%; 11%), P = 0.65) in the LZ and placebo group, respectively, as well as CPR per transfer adjusted for day of transfer, oestradiol and progesterone levels at trigger, progesterone levels mid-luteal, and number of oocytes retrieved (adjusted OR) of 0.8 (95% CI (0.4; 1.6), P = 0.72). Comparable LBR were found per transfer 28% vs 37% (MD -9%, 95% CI (-26%; 9%), P = 0.60) and per randomized women 24% vs 30% (MD of -6%, CI (-22%; 8%), P = 0.60) in the LZ group and placebo group, respectively. Furthermore, 4.8 years since the last oocyte aspiration, a total of 287 of 386 embryos have been transferred in the fresh or a subsequently FET cycle, disclosing the cumulative CPR, which is similar with 38% vs 34% (MD 95% CI (8%; 16%), P = 0.70) in the LZ vs placebo group. LIMITATIONS, REASONS FOR CAUTION: Both cleavage stage and blastocyst transfer and vitrification were permitted in the protocol, making it necessary to categorize their quality and pool the results. The study was powered to detect hormonal variation but not embryo or pregnancy outcomes. WIDER IMPLICATIONS OF THE FINDINGS: The similar utilization rate and quality of the embryos support the use of LZ co-treatment for IVF with specific indication as fertility preservation, patients with previous cancer, or poor responders. The effect of LZ on mature oocytes from different follicle sizes and LBRs should be evaluated in a meta-analysis or a larger RCT. STUDY FUNDING/COMPETING INTEREST(S): Funding was received from EU Interreg for ReproUnion, Sjaelland University Hospital, Denmark, Ferring Pharmaceuticals, and Gedeon Ricther. Roche Diagnostics contributed with assays. A.P. has received grants from Ferring, Merck Serono, and Gedeon Richter, consulting fees from Preglem, Novo Nordisk, Ferring, Gedeon Richter, Cryos, & Merck A/S, speakers fees from Gedeon Richter, Ferring, Merck A/S, Theramex, & Organon, and travel support from Gedeon Richter. The remaining authors declare that they have no competing interests in the research or publication. TRIAL REGISTRATION NUMBERS: NCT02939898 and NCT02946684.
引用
- Bülow NS, Warzecha AK, Nielsen MV, et al. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial. Hum Reprod. 2023. PMID: 37699851. doi:10.1093/humrep/dead182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。